ReviewRegenerative biomaterials2026
Bacterial extracellular vesicles in inflammatory diseases: emerging roles and mechanisms.
Review in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial extracellular vesicles (BEVs), nanoscale membrane-bound particles secreted by bacteria, have emerged as pivotal mediators of host-microbe communication, particularly in the context of inflammatory diseases. By delivering diverse bioactive cargos including proteins, lipids, nucleic acids and metabolites, BEVs orchestrate complex immunological responses, playing dual roles in both the exacerbation and resolution of inflammation. This review presents a comprehensive overview of the biogenesis, classification and molecular composition of BEVs, with emphasis on their immunomodulatory functions. Mechanistically, BEVs derived from pathogenic bacteria can trigger robust pro-inflammatory signaling cascades, disrupt epithelial barriers and promote tissue destruction, contributing to disease progression in conditions such as periodontitis, rheumatoid arthritis and pulmonary disorders. Conversely, BEVs from commensal and probiotic strains exhibit anti-inflammatory and tissue-reparative effects, mediated through macrophage polarization, cytokine modulation and gut microbiota homeostasis. Recent advances highlight the therapeutic potential of engineered BEVs as bio-nanocarriers for targeted drug delivery, vaccine platforms and immunotherapies. We further explore the translational challenges of BEV-based strategies, including scalability, targeting specificity and biocompatibility. By elucidating the multifaceted roles of BEVs in inflammatory pathophysiology, this review offers new insights into their application as next-generation nanotherapeutics for precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.